

Session Title: #19: Cancer Fatigue and Contributing Factors: Recognition and Treatment

Session Type: Education Session

Date: Saturday, June 5

Location: E354b

Time: 8:00 AM - 9:15 AM

- Cancer-Related Fatigue: Who Gets It and How Long Does It Last?
Ann Malone Berger, RN, PhD, AOCN, FAAN
- Do Medications Work to Decrease Cancer-Related Fatigue?
Eduardo Bruera, MD
- Non Pharmacologic Interventions to Decrease Fatigue
Bernadine Cimprich, RN, PhD, CS, FAAN

Session Title: #222: Molecularly Targeted Trials in Lung Cancer

Session Type: Clinical Science Symposium

Date: Saturday, June 5

Location: E Hall D1

Time: 8:00 AM - 9:30 AM

- Molecularly Targeted Trials in Lung Cancer
Heather A. Wakelee, MD
- Molecularly Targeted Trials in Lung Cancer
Marvaretta Miesha Stevenson, MD
- #7500-Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).
Jacek Jassem
- Discussion: IGF1R: Where do we go from here?
D. Ross Camidge, MD, PhD
- #LBA7501-A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.
Joachim Von Pawel

- Discussion: Where does this TRAIL lead us?

Bruce E. Johnson, MD

- #LBA7502-Results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Joan H. Schiller

- Discussion: Combinations of targeted agents

Ravi Salgia, MD, PhD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #125: Improving Outcomes for Patients with Locally Advanced Lung Cancer

Session Type: Clinical Problems in Oncology Session

Date: Saturday, June 5

Location: E451a

Time: 1:15 PM - 2:30 PM

- Surgical Management of Locally Advanced Lung Cancer

Douglas E. Wood, MD

- Stage III NSCLC: Does Better Technology = Better Treatment?

Jeffrey Bogart, MD

- Systemic Therapy for Locally Advanced NSCLC including the Role of Treatment Post Chemoradiotherapy

Julie R. Brahmer, MD

Session Title: #158: Lung Cancer - Local-Regional and Adjuvant Therapy

Session Type: Oral Abstract Session

Date: Saturday, June 5

Location: E Hall D1

Time: 3:00 PM - 5:30 PM

- Lung Cancer - Local-Regional and Adjuvant Therapy
Joe B. Putnam, MD
- Lung Cancer - Local-Regional and Adjuvant Therapy
Katherine Pisters, MD
- #7000-A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study.
Kurt G. Tournoy, Prof., Dr.
- Discussion: Invasive Mediastinal Staging: Necessary and Often Overlooked
Steven M. Keller, MD
- #7002^ -Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.
Tudor-Eliade Ciuleanu, MD, PhD
- Discussion: Small Cell Lung Carcinoma: New Approaches for an Orphan Illness
Bonnie S. Glisson, MD
- #7003-Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer.
Virginie Westeel
- #CRA7004-A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).
Daniel D. Karp
- #LBA7005-A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor, Gefitinib in Completely Resected Stage IB-IIIA Non Small Cell Lung Cancer (NSCLC), NCIC CTG BR.19
Glenwood D. Goss
- Discussion: Evolution of Multimodality Therapy in Early Stage NSCLC
David Harpole, MD

- #LBA7007-A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC).

Panos Fidas, MD

- Discussion: Novel Therapeutics in Non Small Cell Lung Cancer

Julie R. Brahmer, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #115: Controversies in Stage IIIA Non-small Cell Lung Cancer

Session Type: Meet the Professor Session

Date: Sunday, June 6

Location: E451b

Time: 8:00 AM - 9:15 AM

- Controversies in Stage IIIA NSCLC

Renato Martins, MD, MPH

Session Title: #206: Lung Cancer - Local-Regional and Adjuvant Therapy

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

19A #7027-Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model.

Emilio Bria

19B #7028-Prognostic value of three microRNA expression profiles in early-stage squamous cell lung cancer (SqCLC).

Marcin Tomasz Skrzypski

19C #7029-VDAC1 and prognosis in surgically resected non-small cell lung cancer.

Claire ME Grills

19D #7030-Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer.

Derek Weycker

19E #7031-Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection.

Eric S. Kim

19F #7032-Use of serum autoantibodies to identify early-stage lung cancer.

Laura Peek

19G #7033-Demographics of populations at high risk of lung cancer and results of the Early CDT-Lung test.

J. Mathew

19H #7034-Postoperative survivin expression in stage III non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemoradiation.

Mary J. Fidler

20A #7035-Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor.

Ho Yun Lee

20B #7036-Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM).

Anna K. Nowak

20C #7037-CALGB 30601: A phase II study of dasatinib (D) in patients (pts)

20D #7038-A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET.

Sheeba Irshad

20E #7039-A new prognostic score in patients with malignant pleural mesothelioma.

Giovanni Selvaggi

20F #7040-A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM).

Nicla Maria La Verde

20G #7041-Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM).

Elena Lorenzi

20H #7042-Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma.

Anne S. Tsao

21A #7043-A multimodality treatment for malignant pleural mesothelioma patients with or without lymph node metastases.

Keith A Cengel

21B #7044-Phase II trial of consolidation chest radiotherapy for extensive-stage small cell lung cancer.

Don Yee

21C #7045-Pretreatment positron emission tomography (PET) scan standardized uptake value (SUV) as a prognostic variable for overall survival in limited-stage small cell lung cancer (L-SCLC).

Daniel R Gomez

21D #7046-A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC).

Charles M. Rudin, MD, PhD

21E #7047-Should large cell neuroendocrine carcinoma of the lung (LNEC) be classified and treated as a small cell lung cancer (SCLC) or with other large cell carcinomas (OLC)?

Malcolm M. DeCamp

21F #7048-Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive disease (SCLC-ED).

Oliver A. Cornely

21G #7049-Phase II study of irinotecan, carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small-cell lung cancer.

Eric T. Lubiner

21H #7050-Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).

John V Heymach, MD, PhD

22A #7051-Long-acting somatostatin analogues survival differences in limited and extensive disease SCLC patients.

Kostas Zarogoulidis

22B #7052-Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

Mary O'Brien

22C #7053-Retrospective study of irinotecan plus cisplatin induction followed by concurrent thoracic irradiation with irinotecan plus cisplatin chemotherapy for limited-disease small cell lung cancer.

Jaeheon Jeong

22D #7054-A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC).

Naoyuki Nogami

22E #7055-Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC).

David Michael Waterhouse

22F #7056-Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results.

Neal Ready

22G #7057-Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC).

Takashi Hirose

23A #7059-Five-year follow-up of preoperative chemotherapy (Cx) of docetaxel with or without cisplatin for clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Report of a Japan Clinical Oncology Group Study (JCOG0204).

Hideo Kunitoh

23B #7060-Evaluation of neoadjuvant "window of opportunity" trials with targeted therapy in patients with surgically resectable non-small cell lung cancer.

Brendon Matthew Stiles

23C #7061-Does induction chemoradiation effect perioperative mortality and overall survival in patients undergoing pneumonectomy for non-small cell lung cancer?

Jacqueline Oxenberg

23D #7062-Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemotherapy-naive patients with NSCLC stage IB-IIIA (INN06-study): Preliminary results.

Wolfgang Hilbe

23E #7063-Docetaxel plus cisplatin versus vinorelbine plus cisplatin as adjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer: Preliminary result of phase II pilot trial CHL001/TAX622.

Da-Tong Chu

23F #7064-Multimodal management of locally advanced (N2) non-small cell lung cancer (NSCLC): Is there a role for surgical resection? A single institution experience.

Joaquim Bosch-Barrera

23G #7065-The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: A subset analysis of HOG LUN 01-24/USO-023.

Nagesh H. Jayaram

23H #7066-Role of surgery in patients with stage IIIA non-small cell lung cancer (NSCLC): Lessons learned from a tertiary referral cancer center experience.

Charu Aggarwal

24A #7067-Influence of surgical interventions on survival in patients with stage IIIb non-small cell lung cancer (NSCLC): The Fox Chase Cancer Center (FCCC) experience.

Walter J Scott

24B #7068-Surgeon-determined variability in quality of surgical resection of lung cancer.

Robert A. Ramirez, DO

24C #7069-Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer.

Abram Recht, MD

24D #7070-Review of mediastinal lymph node examination (mLNE) in a lung cancer resection (LCR) cohort.

Raymond U. Osarogiagbon

24E #7071-Accuracy of endobronchial ultrasound-directed transbronchial needle aspiration (EBUS-TBNA) for mediastinal staging in patients (pts) with non-small cell lung cancer (NSCLC).

Maria Gabriela Tupayachi

24F #7072-Does the revised TNM staging system for lung cancer better estimate actuarial rates of local/regional recurrence after surgery?

Joseph M. Pepek

24G #7073-Solitary pulmonary nodules (SPNs): Outcome of six-year follow-up by a VA multidisciplinary lung cancer group.

Harvey B. Niell

24H #7074-Examination of the influence that lymphatic and venous involvement gives consequence of stage I non small-cell lung cancer in new TNM classification.

Katsuo Kojima

25A #7075-Racial disparities on the use of invasive and noninvasive staging in patients (pts) with non-small cell lung cancer (NSCLC).

Jennifer Marie Suga

25B #7076-Survival of non-small cell lung cancer (NSCLC) patients in a randomized trial as predicted by the FDG-PET standardized uptake value (SUV).

Karen Y. Gulenchyn

25F #7077-Use of PET-measured response in involved mediastinal lymph nodes to predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with induction therapy (IT) and surgery.

Stephen Barnett

25G #7078-A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.

Joel W. Neal

25H #7079-Health-related quality of life (HRQOL) after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC).

Suresh Senan

26A #7080-Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter study.

Arjun Pennathur

26B #7081-Photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways more than 1.0 cm in diameter.

Jitsuo Usuda

26F #7082-Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update.

Hak Choy

26G #7083-Randomized phase II trial of tegafur-uracil (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small cell lung cancer: NJLCG 0601.

Makoto Maemondo

26H #7084-Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402.

Yuichiro Ohe

27A #7085-N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC).

Steven E. Schild, MD

27B #7086-A phase I dose-escalation study using three-dimensional conformal radiotherapy with concurrent cisplatin and S-1 in patients with stage III non-small cell lung cancer.

Takuyo Kozuka

27C #7087-A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b non-small cell lung cancer (NSCLC).

Anthony M. Brade

27D #7088-Vinorelbine and cisplatin concurrently combined with thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: A long-term safety and efficacy report.

Hidehito Horinouchi

27E #7089-Can we predict two-year survival for radical radiation dosing schedules in advanced non-small cell lung cancer through a meta-analysis based predictive model?

Waseem Sharieff

27F #7090-Docetaxel (D) and cisplatin (C) induction chemotherapy followed by concurrent thoracic radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study.

Joaquin Casal

27G #7091-A Galician Lung Cancer Group phase II study: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC).

Sergio Vazquez

27H #7092-Concomitant pemetrexed/carboplatin chemotherapy and 3-D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: Preliminary results of a phase II study.

Shenlin Ma

28A #7093-Cisplatin (CDDP) and oral vinorelbine (NVBO) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC) treatment: Clinical experience in five institutions in Spain.

Jordi Remon

28B #7094-Outcomes of patients with stage III (clinical N2) NSCLC: A VACCR analysis.

Apar Kishor Ganti, MD

28C #7095-Retrospective review of all patients with thymoma treated over the last 33 years at the Royal Marsden Hospital.

Charlotte Benson

28D #7096-Volumetric analysis of advanced thymic malignancies.

Jeremy Force

28E #7097-Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions.

Ping Yang

28F #7098-Baseline results of lung cancer screening program for family lung cancer risk with low-dose spiral CT in Taiwan.

Chih-Liang Wang

Session Title: #207: Lung Cancer - Metastatic

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

31A #7536-A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Français de Pneumocancerologie (GFPC)*0504

Herve Le Caer

31B #7537-Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).

Tony Mok, MD

31C #7538-EGFR and *ABCG2* polymorphisms as prognostic and predictive markers in the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell lung cancer (NSCLC).

Geoffrey Liu

32A #7539-Clinical impact of amphiregulin expression in EGFR wild-type non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

Myung Hee Chang

32B #7540-Biomarker analyses from a phase I study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).

Enriqueta Felip

32C #7541-Association of *KRAS* and *EGFR* mutations with survival in patients with advanced lung adenocarcinoma.

Melissa Lynne Johnson

33A #7542-EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer.

April F. Eichler

33B #7543-Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib.

Stephanie Heon

33C #7544-Clinicopathologic differences between lung cancer with EGFR gene major (exon 19 deletions and exon 21 L858R) and other minor mutations.

Yuki Yamane

34A #7545-The usefulness of 18f-fluorothymidine (FLT) and 18f-FDG PET for early prediction of response to erlotinib therapy in patients with advanced non-small cell lung cancer.

Chang-Min Choi

34B #7546-Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastasized non-small cell lung cancer (NSCLC): results of the nonrandomized phase II study TaxErb.

Jurgen R. Fischer

34C #7547-A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC).

Byoung Chul Cho

35A #7548-Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers.

Christopher Harbison

35B #7549-Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion.

Miquel Taron

35C #7550-Association of epithelial mesenchymal transition (EMT) markers and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib.

Neel Bhupendra Shah

35D #7551-Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Jin Seok Ahn

35E #7552-The association between *PTEN* expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib.

Thomas A. Hensing

35F #7553-Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy.

Reem Karmali

35G #7554-SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).

Belinda A. Waltman

35H #7555-Expression of MET, IGF-1R, IL-6/gp130, and AXL in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.

Carlota Costa

36A #7556-First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology.

Kenneth John O'Byrne

36B #7557-Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Gregory J. Riely, MD, PhD

36C #7558-Association of gender and passive smoking with epidermal growth factor receptor mutations in never-smokers with non-small cell lung cancer: A prospective study based on detailed passive smoking questionnaire.

Tomoya Kawaguchi

36D #7559-A phase II study of gefitinib versus vinorelbine or gemcitabine in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer based on epidermal growth factor receptor mutation status.

Shiro Fujita, MD, PhD

36E #7560-Assessment of epidermal growth factor receptor (EGFR) and K-ras mutation status in cytologic stained smears of non-small cell lung cancer (NSCLC) patients.

Maria Dolores Lozano

36F #7561-First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study).

Yuji Minegishi

36G #7562-Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations.

Vienna Ludovini

36H #7563-Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma.

Kazuo Kasahara

37A #7564-Effect of tumor-specific KRAS mutational status on impact of anti-EGFR therapy in non-small cell lung cancer (NSCLC).

Marina Chiara Garassino

37B #7565-Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group.

Martin Reck

37C #7566-Comparison of adverse events of erlotinib with those of gefitinib in Japanese patients with NSCLC.

Tomohiro Suzumura, MD

37D #7567-Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E).

Linda Mileschkin

37E #7568-Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC).

Mark R. Green

37F #7569-Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC.

Miguel Angel Villalona-Calero, MD

37G #7570-Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small cell lung cancer (NSCLC) patients (p).

Sara Simonetti

37H #7571-The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.

Akira Inoue

38A #7572-Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

Wee-Lee Yeo

38B #7573-Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Atsushi Horiike

38C #7574-A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China.

Qiong Zhao, MD

38D #7575-Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL).

Caicun Zhou

38E #7576-Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC).

Tom Stinchcombe, MD

38F #7577-First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small cell lung cancer patients.

Chien-Hao Lie, MD

38G #7578-Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC).

Davide Tassinari

38H #7579-Comparison of response rate of advanced non-small lung cancer patients to liposomal cisplatin versus cisplatin both combined with paclitaxel: A phase III trial.

George Stathopoulos

39A #7580-Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

Ramaswamy Govindan, MD

39B #7581-Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results.

Silvia Novello, MD, PhD

39F #7582-Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer.

Charles Lu

39G #7583-BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC).

Leonardo Faoro

39H #7584-A randomized phase III study of cisplatin and docetaxel with or without irinotecan in pts with advanced non-small cell lung cancer: Okayama Lung Cancer Study Group OLCSG 0403.

Katsuyuki Kiura

40A #7585-Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).

Merrill S. Kies, MD

40B #7586-Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC).

Takashi Seto

40F #7587-Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial.

Edward Garon

40G #7588-A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

D. Ross Camidge, MD, PhD

40H #7589-Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results.

Raghunadharao Digumarti

41A #7590-Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results.

Ross A. Soo, MD

41B #7591-First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial.

Jun Liang

41C #7592-Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC).

Alain C. Mita

41D #7593-A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.

David R. Spigel

41E #7594-Phase II study of dasatinib in patients with advanced non-small cell lung cancer.

Faye M. Johnson

41F #7595-Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with measurable asymptomatic inoperable brain metastases (BM): A multicenter phase II trial (GFPC 07-01).

Gilles Robinet

41G #7596-PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E).

Alicyn Campbell

41H #7597-Phase III study comparing vinorelbine/gemcitabine with vinorelbine/carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial.

Øystein Fløtten

42A #7598-Results of phase IV clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC).

Jinwan Wang

42B #7599-PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study.

Keunchil Park

42C #7600-A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC.

Gideon Michael Blumenthal

42D #7601-Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer.

Dianna Shipley

42E #7602-A nonrandomized, multicenter, phase II study of S-1 with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

Dennie V. Jones

42F #7603-A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

Grace K. Dy

42G #7604-Final results of a phase II trial of S-1 with biweekly docetaxel for non-small cell lung cancer previously treated with platinum-based chemotherapy (NJLCG0701).

Osamu Ishimoto

42H #7605-Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase III Hellenic Oncology Research Group trial.

Athanasios Karampeazis

43A #7606-Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer.

Alice Tsang Shaw

43B #7607-Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501.

Wu Zhang

43D #7609-Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.

Roy S. Herbst

43E #7610-EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients.

Giuseppe Altavilla

43F #7611-Molecular profiling of smoking-related non-small cell lung cancer (NSCLC) phenotypes.

John H. Strickler

43G #7612-In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC).

Rebecca Suk Heist

43H #7613-Eicosanoids in non-small cell lung cancer (NSCLC).

David H. Johnson, MD, FACP

44A #7614-Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.

Martin J. Edelman, MD

44B #7615-Correlation of pharmacogenetic markers with docetaxel-based chemotherapy resistance in patients with advanced/metastatic non-small cell lung cancer.

Chara Papadaki

44C #7616-Correlation of genetic polymorphisms in folate metabolic pathway genes with clinical outcomes in pemetrexed-treated advanced NSCLC patients.

Jung A. Kim

44D #7617-Phase II trial of personalized chemotherapy in stage IV NSCLC: Clinical application of functional profiling in first-line therapy.

Robert Alan Nagourney

44E #7618-Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS).

Antoinette J. Wozniak

44F #7619-Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS).

Priya Kumar

44G #7620-Expression of sonic hedgehog and its receptor patched in non-small cell lung cancer.

Omid Rouhi

44H #7621-DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma (NSLA).

Ji-Youn Han

45A #7622-Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial.

James R. Rigas

45B #7623-Time trend in treatment-related deaths of patients with advanced non-small cell lung cancer enrolled into phase III trials of systemic treatment.

Yoshiro Fujiwara

45C #7624-Progression-free survival (PFS) and overall survival (OS) in phase III trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).

Katsuyuki Hotta

45D #7625-Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis.

Gaetan Des Guetz

45E #7626-Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S).

Ronan Joseph Kelly

45F #7627-Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes.

Ling Zhang

45G #7628-Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer.

Silke Nagel

45H #7629-Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials.

Sumithra J. Mandrekar

46A #7630-Circulating tumor cells (CTC) in small cell lung cancer (SCLC), a promising prognostic factor.

Thijo Jeroen Nicolaas Hiltermann, MD, PhD

46B #7631-ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.

Michael Schuster

46C #7632-HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.

Suchita Pakkala

46D #7633-Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis.

Taofeek Kunle Owonikoko, MD

46E #7634-First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project.

Jonathan L. Vandergrift

46F #7635-Brain metastases (mets) in lung cancer patients (pts): Analysis of the Detroit Surveillance, Epidemiology and End Results (SEER) data.

Shirish M. Gadgeel, MD

46G #7636-Prognostic impact of malignant pleural effusion in patients with stage M1b non-small cell lung cancer.

Daniel Morgensztern

46H #7637-Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

Nathan R Foster

47A #7638-Ethnic difference in toxicity in non-small cell lung cancer patients treated with chemotherapy: A systematic review on phase II and III clinical trials.

Yoshikazu Hasegawa

47B #7639-Improving the accuracy of FNA lung biopsies in a community hospital.

Ashantice Higgins, MD

Session Title: #104: Therapy for Patients with Activating Mutations of the Epidermal Growth Factor Receptor

Session Type: Education Session

Date: Sunday, June 6

Location: N Hall B1

Time: 9:45 AM - 11:00 AM

- Mechanisms of resistance to EGFR inhibitors

William Pao, MD, PhD

- Testing for EGFR in Untreated Patients: Implications for Treatment

Tony Mok, MD

- Therapy after progression in first line for patients with activating mutation of the EGFR

David Michael Jackman, MD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

Douglas W. Blayney, MD

- Plenary Session including Science of Oncology Award and Lecture

Daniel F. Hayes, MD

- Plenary Session including Science of Oncology Award and Lecture

Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Elisabeth A. Quoix

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

- Discussion: Cancer Prevention/Epidemiology

Scott Michael Lippman, MD

Session Title: #54: Health Disparities in Lung Cancer: Race, Sex, and Genes

Session Type: Education Session

Date: Monday, June 7

Location: E Hall D2

Time: 8:00 AM - 9:15 AM

- Molecular Epidemiology of Lung Cancer: Ancestry Matters

Alex A. Adjei, MD, PhD

- Molecular Genetic Variations Between Human Populations
Patrick C. Ma, MD, MSc
 - Impact of Gender on Incidence, Behavior, and Therapy of Lung Cancer
Nithya Ramnath, MD
-

Session Title: #186: Lung Cancer - Metastatic

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: E450b

Time: 8:00 AM - 12:00 PM

- Lung Cancer - Metastatic
Taofeek Kunle Owonikoko, MD
- Lung Cancer - Metastatic
Shirish M. Gadgeel, MD

1 #7512-Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer.

Andreas Claudius Hoffmann

2 #7513-Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy.

David R. Gandara

3 #7514-Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

Rafael Rosell

5 #7516-Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.

Bruce E. Johnson, MD

6 #7517-Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

Lecia Sequist, MD

- Discussion: Biomarkers

Michael J. Kelley, MD

7 #7518-A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03).

Rabab Mohamed Gaafar

8 #7519-Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

Lampros Vamvakas

9 #7520-Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

Geoffrey Raymond Oxnard

10 #7521[^]-A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

Chih-Hsin Yang

11 #7522-Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504).

Suresh S. Ramalingam, MD

12 #LBA7523-Efficacy and safety of PF299804 versus (v) erlotinib (E): a global, randomized phase (P) 2 trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).

Michael J. Boyer

13 #7524-Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

Natasha B. Leigh

- Discussion: New approaches in EGFR targeted therapy

Karen L. Reckamp, MD, MS

14 #7525-Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

Jin Soo Lee

15 #7526-Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with b for first-line treatment of locally advanced, recurrent, or metastatic non­-small cell lung cancer (NSCLC).

Fairooz F. Kabbinavar

16 #7527-A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC).

Baohui Han

17 #7528-Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

George R Blumenschein, Jr, MD

- Discussion: Anti-angiogenic agents

Silvia Novello, MD, PhD

19 #7530-Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605).

Hiroshige Yoshioka

20 #7531-Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

Thomas James Lynch

22 #7533-Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).

Primo Lara, MD

23 #7534-A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC).

Fiona Hellen Blackhall

24 #7535-Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

Christos Stelios Karapetis

- Discussion: New agents

Suresh S. Ramalingam, MD

Session Title: #93: Seminal Advances in Lung Cancer Research 2010: Translational and Clinical

Session Type: Education Session

Date: Monday, June 7

Location: E Hall D1

Time: 9:45 AM - 11:00 AM

- Translational Advances in Lung Cancer

Ravi Salgia, MD, PhD

- Clinical Advances in Lung Cancer
Ramaswamy Govindan, MD
 - Perspectives on Recent Advances in Lung Cancer
Jeffrey Crawford, MD
-

Session Title: #253: Lung Cancer - Metastatic

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: E Hall D1

Time: 12:00 PM - 1:00 PM

- Lung Cancer - Metastatic
Taofeek Kunle Owonikoko, MD
- Lung Cancer - Metastatic
Shirish M. Gadgeel, MD

1 #7512-Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer.

Andreas Claudius Hoffmann

2 #7513-Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy.

David R. Gandara

3 #7514-Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

Rafael Rosell

5 #7516-Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.

Bruce E. Johnson, MD

6 #7517-Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

Lecia Sequist, MD

- Discussion: Biomarkers

Michael J. Kelley, MD

7 #7518-A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03).

Rabab Mohamed Gaafar

8 #7519-Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

Lampros Vamvakas

9 #7520-Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

Geoffrey Raymond Oxnard

10 #7521[^]-A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

Chih-Hsin Yang

11 #7522-Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504).

Suresh S. Ramalingam, MD

12 #LBA7523-Efficacy and safety of PF299804 versus (v) erlotinib (E): a global, randomized phase (P) 2 trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).

Michael J. Boyer

13 #7524-Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

Natasha B. Leigh

- Discussion: New approaches in EGFR targeted therapy

Karen L. Reckamp, MD, MS

14 #7525-Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

Jin Soo Lee

15 #7526-Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with b for first-line treatment of locally advanced, recurrent, or metastatic non­-small cell lung cancer (NSCLC).

Fairooz F. Kabbinavar

16 #7527-A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC).

Baohui Han

17 #7528-Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

George R Blumenschein, Jr, MD

- Discussion: Anti-angiogenic agents

Silvia Novello, MD, PhD

19 #7530-Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605).

Hiroshige Yoshioka

20 #7531-Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

Thomas James Lynch

22 #7533-Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).

Primo Lara, MD

23 #7534-A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC).

Fiona Hellen Blackhall

24 #7535-Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

Christos Stelios Karapetis

- Discussion: New agents

Suresh S. Ramalingam, MD

Session Title: #262: ASCO/ECCO Joint Session: Personalized Medicine in Locally Advanced Non-small Cell Lung Cancer

Session Type: Special Session

Date: Monday, June 7

Location: E Arie Crown Theater

Time: 1:15 PM - 2:30 PM

- Introduction - The Need for Personalized Medicine in Locally Advanced NSCLC

- Tumor Biology and Its Impact on Decision-making (assay technology)

David Paul Carbone, MD, PhD

- Multidisciplinary Localized Therapy Innovative Developments in Multidisciplinary Treatments of NSCLC

Michael Brada, MD

- Systemic Therapy - What Lies Ahead?

Jean-Charles Soria, MD, PhD

- Summary - The Future of Personalized Medicine

Douglas W. Blayney, MD

Session Title: #66: Maintenance Chemotherapy for Non-small Cell Lung Cancer: Effectiveness and Cost-effectiveness

Session Type: Education Session

Date: Monday, June 7

Location: S404

Time: 3:00 PM - 4:15 PM

- Maintenance therapy for advanced NSCLC is standard of care

Tracey L. Evans, MD

- Maintenance therapy for advanced NSCLC is not standard of care

Tom Stinchcombe, MD

- Cost effectiveness in lung cancer trials and treatment

Scott Ramsey, MD, PhD

Session Title: #159: Lung Cancer - Metastatic

Session Type: Oral Abstract Session

Date: Monday, June 7

Location: E Hall D2

Time: 3:00 PM - 5:30 PM

- Lung Cancer - Metastatic

Lecia Sequist, MD

- Lung Cancer - Metastatic

Nithya Ramnath, MD

- #7503-Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.

Pasi A. Janne, MD, PhD

- #7504-TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy.

Siow Ming Lee, MD, PhD, FRCP

- Discussion: EGFR inhibitors: Are we done yet?

Fadlo Raja Khuri, MD

- #7506-Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).

Chandra Prakash Belani, MD

- #7507-Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

Maurice Perol

- #7508-International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial.

Cesare Gridelli, MD

- Discussion: Optimizing Care in Advanced Lung Cancer

Gregory Peter Kalemkerian, MD

- #7509-Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial.

Jennifer S. Temel

- #LBA7511-Results of a Randomized, Phase 3 Trial of *nab*-Paclitaxel (*nab*-P) and Carboplatin (C) Compared With Cremophor-based Paclitaxel (P) and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Cancer (NSCLC)

Mark Anthony Socinski

- Discussion: Optimizing Care in Advanced Lung Cancer

Raffit Hassan, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III
Kathy Miller, MD
- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy
Kathy Miller, MD
- Discussion: Lung Cancer - Metastatic
Charles M. Rudin, MD, PhD
- Discussion: Sarcoma
Gary K. Schwartz, MD
- Discussion: Gastrointestinal (Noncolorectal) Cancer
C. D. Blanke, MD
- Discussion: Head and Neck Cancer
Everett E. Vokes, MD

Session Title: #42: Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment

Session Type: Education Session

Date: Tuesday, June 8

Location: E353

Time: 8:00 AM - 9:15 AM

- Non-surgical staging of the mediastinum
Scott Shofer, MD, PhD
- Lobectomies for small or non-invasive lung cancers: Going, going, gone?
Harvey I. Pass, MD
- Outcome of early stage NSCLC treated with SBRT
Andrea Bezjak, MD

Session Title: #128: Debates in Adjuvant Therapy: Chemotherapy versus Observation for Node-negative Non-small Cell Lung Cancer and Radiotherapy versus Observation for Node-positive Non-small Cell Lung Cancer

Session Type: Clinical Problems in Oncology Session

Date: Tuesday, June 8

Location: E451a

Time: 8:00 AM - 9:15 AM

- Is There a Role for Adjuvant Chemotherapy for Node Negative NSCLC?

Katherine Pisters, MD

- Neo-Adjuvant Versus Adjuvant Chemotherapy for Early Stage NSCLC; Does Pre versus Post Really Matter?

Heather A. Wakelee, MD

- When Should One Consider Adjuvant Radiotherapy for Resected NSCLC?

Christopher Ryan Kelsey, MD

Session Title: #185: Lung Cancer - Local-Regional and Adjuvant Therapy

Session Type: Poster Discussion Session

Date: Tuesday, June 8

Location: E450b

Time: 8:00 AM - 12:00 PM

- Lung Cancer - Local-Regional and Adjuvant Therapy

Corey J. Langer, MD

- Lung Cancer - Local-Regional and Adjuvant Therapy

Joseph Kamel Salama, MD

1 #7008-Impact of *KRAS* mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633.

Marzia Capelletti

2 #7009-Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma.

Mark G. Kris

3 #7010-Association of genetic variations in DNA-methyltransferases, histone-methyltransferases, and methylated DNA-binding proteins with recurrence and survival in early-stage non-small cell lung cancer treated with surgery alone or surgery and chemotherapy.

5 #7012-Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.

Yanis Bellil

6 #7013-KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424.

Philip C. Mack

- Discussion: Biomarkers in Early Stage NSCLC: Has the future arrived?

John V Heymach, MD, PhD

7 #7014-Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC).

Linda E. Coate

8 #7015-A multinational pooled analysis of 434 cases of stage I non-small cell lung cancer (NSCLC) treated with volumetrically image-guided (VIGRT) stereotactic lung radiotherapy (SBRT): Results from the Elekta Collaborative Lung Research Group.

Inga S. Grills

9 #7016-Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations.

Raymond H. Mak

- Discussion: New Directions for Radiotherapy in NSCLC

Jeffrey Bogart, MD

10 #7017-Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) outcomes database project.

Carrie Zornosa, MS

11 #7018-Adoption of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes study.

Christopher M. Booth, MD

12 #7019-A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.

He Jie

13 #7020-IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.

Gerard Zalcman

- Discussion: Surgical Perspective on Systemic Therapy for NSCLC and Mesothelioma

William Roy Smythe, MD

14 #7021-Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030).

Juan J. Fibla

15 #7022-The impact of stage migration on survival after resection in the UICC 7 TNM classification of lung cancer.

Jan P. Van Meerbeeck

16 #7023-Prognostic significance of the number of tumor (+) N2 nodes in N2 stage IIIA non-small cell lung cancer after curative resection.

Changhoon Yoo

17 #7024-RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC.

Mohan Suntharalingam, MD

18 #7025-Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806).

Masahiro Tsuboi

19 #7026-Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survival of patients with marginally resectable SST.

Ritsuko Komaki

- Discussion: Alternative Approaches to Advanced Resectable NSCLC

Jessica S. Donington, MD

Session Title: #95: Supportive Care for Patients with Non-small Cell Lung Cancer

Session Type: Education Session

Date: Tuesday, June 8

Location: E353

Time: 9:30 AM - 10:45 AM

- Management of dyspnea and pleural effusion in patients with lung cancer

David Feller-Kopman, MD

- Ancillary therapy for bone mets in the age of bisphosphonates

Vera Hirsh, MD

- Management of brain metastases in lung cancer patients.

Minesh P. Mehta, MD

Session Title: #252: Lung Cancer - Local-Regional and Adjuvant Therapy

Session Type: Poster Discussion Session

Date: Tuesday, June 8

Location: E354b

Time: 12:00 PM - 1:00 PM

- Lung Cancer - Local-Regional and Adjuvant Therapy

Corey J. Langer, MD

- Lung Cancer - Local-Regional and Adjuvant Therapy

Joseph Kamel Salama, MD

1 #7008-Impact of *KRAS* mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633.

Marzia Capelletti

2 #7009-Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma.

Mark G. Kris

3 #7010-Association of genetic variations in DNA-methyltransferases, histone-methyltransferases, and methylated DNA-binding proteins with recurrence and survival in early-stage non-small cell lung cancer treated with surgery alone or surgery and chemotherapy.

Klaus Wolfgang Wagner

4 #7011-Impact of *EGFR* and *KRAS* mutations on survival in 1,000 patients with resected lung adenocarcinoma.

Sandra P. D'Angelo

5 #7012-Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.

Yanis Bellil

6 #7013-*KRAS* and *EGFR* mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424.

Philip C. Mack

- Discussion: Biomarkers in Early Stage NSCLC: Has the future arrived?

John V Heymach, MD, PhD

7 #7014-Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC).

Linda E. Coate

8 #7015-A multinational pooled analysis of 434 cases of stage I non-small cell lung cancer (NSCLC) treated with volumetrically image-guided (VIGRT) stereotactic lung radiotherapy (SBRT): Results from the Elekta Collaborative Lung Research Group.

Inga S. Grills

9 #7016-Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations.

Raymond H. Mak

- Discussion: New Directions for Radiotherapy in NSCLC

Jeffrey Bogart, MD

10 #7017-Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) outcomes database project.

Carrie Zornosa, MS

11 #7018-Adoption of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes study.

Christopher M. Booth, MD

12 #7019-A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIa non-small cell lung cancer (NSCLC): An interim preliminary result.

He Jie

13 #7020-IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.

Gerard Zalcman

- Discussion: Surgical Perspective on Systemic Therapy for NSCLC and Mesothelioma

William Roy Smythe, MD

14 #7021-Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030).

Juan J. Fibla

15 #7022-The impact of stage migration on survival after resection in the UICC 7 TNM classification of lung cancer.

Jan P. Van Meerbeeck

16 #7023-Prognostic significance of the number of tumor (+) N2 nodes in N2 stage IIIA non-small cell lung cancer after curative resection.

Changhoon Yoo

17 #7024-RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC.

Mohan Suntharalingam, MD

18 #7025-Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806).

Masahiro Tsuboi

19 #7026-Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survival of patients with marginally resectable SST.

Ritsuko Komaki

- Discussion: Alternative Approaches to Advanced Resectable NSCLC

Jessica S. Donington, MD